In clinical studies, patients using semaglutide lost an average of about 15% of their body weight over 68 weeks when paired with lifestyle changes
Many people confuse metformin with GLP-1 medications because both address blood sugar and weight, but they work through completely different biological pathways
In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg
Alcohol may worsen common GLP-1 side effects including nausea, vomiting, and gastrointestinal discomfort
While some appreciate the ease, others report no effect and frequent issues with shipping or support